Vebreltinib
Phase 3Small molecule
Vebreltinib is one of 116 small molecule programs targeting Metastatic. It is currently in Phase 3.
5
Indications
6
Total Trials
6
Active Trials
115
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
449 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Dato-Dxd
AstraZenecaPhase 3
Monalizumab
AstraZenecaPhase 3
Vebreltinib
AAvistone Biotechnology Co., Ltd.
Phase 3
TGRX-326
SShenzhen TargetRx Co., Ltd.
Phase 3
Remeron
OOrganon and Co
Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Valemetostat Tosylate
Daiichi SankyoPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Locally Advanced or Metastatic NSCLC2 trials
Metastatic1 trial
Vebreltinib for Advanced or Metastatic CCS
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT07153887·30 enrolled
MET Amplification1 trial
Advanced NSCLC1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Vebreltinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- AAvistone Biotechnology Co., Ltd.